Massive Earnings Shocks! 3M, Walgreens, PG & JNJ Results Explained!

00:13:32
https://www.youtube.com/watch?v=bUWh2SarlAU

Summary

TLDRIn this video, the performance of the market is evaluated as stock prices have remained strong, with investor sentiment shifting from fear to a neutral stance. Key earnings reports from major companies like 3M, Procter & Gamble, Johnson & Johnson, and Walgreens reveal varied results, with 3M and Johnson & Johnson showing positive growth while Walgreens faces legal challenges affecting its valuation. Procter & Gamble exhibits moderate revenue growth despite increased consumer price sensitivity. The analysis includes price targets, earnings per share performance, and comparisons to market expectations, exploring the broader implications of economic factors such as tariffs on these companies.

Takeaways

  • 📈 Market shows strong performance with rising investor sentiment.
  • 💰 3M beats earnings expectations, showing solid revenue growth.
  • 💊 Walgreens suffers stock drop due to DOJ lawsuit on opioids.
  • 🏠 Procter & Gamble experiences slight revenue growth amid price sensitivity.
  • 📉 Johnson & Johnson presents significant undervaluation opportunities.

Timeline

  • 00:00:00 - 00:05:00

    The market showed strength with a movement toward neutral in the fear and greed index. Companies reporting earnings included 3M, Procter & Gamble, Johnson & Johnson, and Walgreens, amidst concerns over tariffs and their potential market impact. 3M reported strong earnings with earnings per share of 1.68, surpassing expectations. However, their long-term growth has faced challenges against inflation rates, trading at the upper limit of its 52-week range with mixed analyst ratings and a cut in dividends, making it appear overvalued at current estimates.

  • 00:05:00 - 00:13:32

    Walgreens, meanwhile, faced a significant drop in stock due to a lawsuit from the Department of Justice regarding opioid prescription practices, resulting in a 10% decline. Its current yield is high but comes with substantial risks. Procter & Gamble beat earnings expectations, citing stable household demand but facing inflationary pressures. Lastly, Johnson & Johnson surpassed sales forecasts, particularly in its cancer drug segment, reflecting overall positive earnings although trading near its 52-week low. Despite recent struggles, Johnson & Johnson shows potential for future growth with favorable analyst ratings.

Mind Map

Video Q&A

  • What is the current state of the market according to the video?

    The market is nearly green across the board, with the fear and greed index sitting at 42, approaching neutral territory.

  • Which companies were covered in the video?

    The video covers 3M, Procter & Gamble, Johnson & Johnson, and Walgreens.

  • How did 3M perform in its latest earnings report?

    3M reported earnings per share (EPS) of 1.68, beating the expected 1.66, and revenue of $6 billion, exceeding the anticipated $5.8 billion.

  • What is Walgreens facing that negatively impacted its stock?

    Walgreens faced a lawsuit from the Department of Justice regarding opioid prescriptions, causing its stock to drop significantly.

  • How did Procter & Gamble perform in its earnings report?

    Procter & Gamble beat earnings estimates slightly with EPS of 1.88 compared to 1.86, and revenue of $2.88 billion compared to $2.54 billion.

  • What is the yield for Johnson & Johnson?

    Johnson & Johnson offers a dividend yield of around 3.37%.

  • What does the forward P/E ratio indicate for Johnson & Johnson?

    Johnson & Johnson's forward P/E is just below 14, suggesting significant undervaluation compared to the sector average.

  • What is the market's outlook for Johnson & Johnson according to Wall Street?

    Wall Street sees a 22% upside for Johnson & Johnson with a price target of $174.

View more video summaries

Get instant access to free YouTube video summaries powered by AI!
Subtitles
en
Auto Scroll:
  • 00:00:00
    yesterday was a fairly strong day for
  • 00:00:02
    the market nearly green right across the
  • 00:00:04
    board and if we look at the fear and
  • 00:00:06
    greed index now we are sitting 42 moving
  • 00:00:09
    into neutral territory very shortly and
  • 00:00:12
    it wasn't long ago that we were sitting
  • 00:00:14
    on the boundary of extreme fear however
  • 00:00:16
    investor sentiment can change very
  • 00:00:19
    quickly and with earnings kicking off
  • 00:00:21
    this is what we want to take a look at
  • 00:00:22
    today where is the market how are the
  • 00:00:24
    companies performing and there a number
  • 00:00:27
    that we want to cover we're going to
  • 00:00:28
    look at 3M we're also going to cover
  • 00:00:30
    Proctor and Gamble as well as Johnson
  • 00:00:32
    Johnson that reported today and some
  • 00:00:34
    interesting news that we got from
  • 00:00:36
    Walgreens now Donald Trump was
  • 00:00:38
    inaugurated just a few days ago and
  • 00:00:41
    there is a lot of talk about tariffs how
  • 00:00:43
    they're going to affect the wider
  • 00:00:44
    economy and whether or not this will
  • 00:00:47
    cause some issues for the market and as
  • 00:00:49
    always we will keep up to date as and
  • 00:00:51
    when we hear now the first company we do
  • 00:00:54
    want to discuss is 3M which did have a
  • 00:00:56
    fairly strong earnings in fact the
  • 00:00:58
    shares were up as we will show you and
  • 00:01:00
    they had a 168 EPS with the market
  • 00:01:03
    anticipating 166 and their sales of 6
  • 00:01:06
    billion was very strong when we compare
  • 00:01:09
    the market wanted around 5.8 billion now
  • 00:01:12
    we can also take a look at other impacts
  • 00:01:14
    of the news and the first one that we do
  • 00:01:16
    want to talk about is that their
  • 00:01:18
    comparable sales as we can in fact see
  • 00:01:20
    did grow by around 2.1% year on year
  • 00:01:23
    something you need to understand with
  • 00:01:24
    this company it isn't fast growing and
  • 00:01:27
    over the longer term it has struggled to
  • 00:01:29
    really keep up in line with the 4%
  • 00:01:31
    inflation rate we continue to talk about
  • 00:01:33
    and organic sales alone were up around
  • 00:01:35
    1% nonetheless it was very strong in
  • 00:01:38
    comparison to what the analyst wanted
  • 00:01:40
    and we also see that in terms of the
  • 00:01:42
    full year they are anticipating around
  • 00:01:44
    760 to 790 which is actually in the
  • 00:01:47
    region of the 778 that the market wants
  • 00:01:50
    and ultimately when it first got
  • 00:01:51
    released yesterday the shares were up
  • 00:01:53
    around 4 and half% if we take a look at
  • 00:01:55
    the company well it is up around 36%
  • 00:01:58
    over the last year as noted over
  • 00:02:00
    yesterday it was up around 4% nearly at
  • 00:02:03
    5 and if you've been a longer term
  • 00:02:05
    shareholder of this company quite
  • 00:02:07
    disappointing you would be down 14% in
  • 00:02:10
    fact we can see alltime highs you'd have
  • 00:02:12
    to go back to around 7 years to day at
  • 00:02:15
    $259 and right now it is trading pretty
  • 00:02:18
    much at the upper end of the 52 we range
  • 00:02:21
    and that is
  • 00:02:22
    $150 we do however notice just one buy
  • 00:02:25
    rating today with Wall Street and they
  • 00:02:27
    do pay a dividend one that was cut not
  • 00:02:29
    too long ago and sits around
  • 00:02:32
    1.99% if you want to look at their
  • 00:02:34
    earnings on a historical basis well what
  • 00:02:36
    we do quite like to see is the 100%
  • 00:02:38
    track record they've outperformed over
  • 00:02:40
    the last four quarters but interesting
  • 00:02:42
    to note that the next quarter they do
  • 00:02:44
    expect quite a substantial drop to the
  • 00:02:46
    EPS with the subsequent three becoming
  • 00:02:49
    positive now they should give you faith
  • 00:02:50
    that they can based on their 100%
  • 00:02:53
    historical accuracy hit the 779 estimate
  • 00:02:56
    for 2025 which means right now their
  • 00:02:58
    forward PE does it around 18.9 and if we
  • 00:03:01
    were to take a look at this in relation
  • 00:03:03
    to the sector median it does sit lower
  • 00:03:05
    in fact if you're someone who has been
  • 00:03:07
    buying now you would be getting a 11%
  • 00:03:10
    discount to the overall comparative
  • 00:03:12
    however we do want to point out that the
  • 00:03:14
    5year average PE does sit around 15.5
  • 00:03:17
    meaning it is around 22% more expensive
  • 00:03:20
    than the average we can also show you
  • 00:03:22
    that based on dividend yield Theory this
  • 00:03:23
    does look to be overvalued remember this
  • 00:03:25
    tells us a company is undervalued when
  • 00:03:28
    the current yield sits above the 5 years
  • 00:03:30
    however one thing we would say is we're
  • 00:03:31
    not going to use this today on the basis
  • 00:03:33
    that they did cut their dividend so it
  • 00:03:35
    does seem to be unreasonable however
  • 00:03:37
    what we will pinpoint and we already
  • 00:03:39
    just discussed in terms of comparison
  • 00:03:41
    against the 5year average Triple M does
  • 00:03:44
    currently trade above that quite
  • 00:03:45
    significantly which can be a signal of
  • 00:03:48
    overvaluation in terms of looking at the
  • 00:03:50
    value this is what we want to do for
  • 00:03:51
    each of these companies today we see it
  • 00:03:53
    at
  • 00:03:54
    $148 which as you can see has been
  • 00:03:56
    derived from the DCF model now we've put
  • 00:03:58
    the numbers through the free cash flow
  • 00:04:00
    year onye where the average growth looks
  • 00:04:02
    to be around 1.4% year onye over the
  • 00:04:05
    period so we've gone 1% moving forwards
  • 00:04:07
    with the discount rate we get the
  • 00:04:09
    present value of future free cash flows
  • 00:04:10
    and terminal value add together with the
  • 00:04:12
    cash subtract total debt get to the
  • 00:04:14
    equity value divide by the shares
  • 00:04:16
    outstanding and we get to the 148 which
  • 00:04:18
    as we can see here in fact is around the
  • 00:04:21
    current value meaning that we believe
  • 00:04:22
    this company isn't trading at a discount
  • 00:04:25
    it's trading right in line with the fair
  • 00:04:27
    value now we do mention this because
  • 00:04:29
    typically on the the channel we like to
  • 00:04:30
    apply a 10% margin of safety we execute
  • 00:04:33
    on this if it meets the three golden
  • 00:04:35
    criteria wide Moe strong financial
  • 00:04:37
    metrics and good forward-looking data if
  • 00:04:40
    you believe that in today's episode
  • 00:04:41
    we'll abide around
  • 00:04:43
    $133 and we typically keep going to it's
  • 00:04:45
    near the current trading price but as it
  • 00:04:47
    is currently trading right now at its
  • 00:04:49
    fair value if you were looking at
  • 00:04:51
    something like 20% that would be around
  • 00:04:53
    the
  • 00:04:54
    $119 Mark we also noticed Wall Street
  • 00:04:56
    themselves believe very minimal upside
  • 00:04:58
    into the end of 2025 $152 price target
  • 00:05:02
    with upside of 3% and remember you can
  • 00:05:05
    grab a copy of this model by click on
  • 00:05:07
    the pin comment below running through
  • 00:05:08
    your own numbers whether it's for 3M or
  • 00:05:10
    any others we then move on to Walgreens
  • 00:05:13
    which was actually down around 10% after
  • 00:05:15
    the Department of Justice had a lawsuit
  • 00:05:17
    around opioids now we can in fact see
  • 00:05:20
    the department did announce they are
  • 00:05:21
    suing the company claiming that the
  • 00:05:23
    pharmacist filled millions of
  • 00:05:25
    prescriptions that actually lacked a
  • 00:05:27
    legitimate medical purpose and then sort
  • 00:05:30
    reimbursements from federal health
  • 00:05:31
    programs in fact it was down as much as
  • 00:05:34
    133% quite large news and if we are to
  • 00:05:37
    look at this right now it is trading at
  • 00:05:39
    a negative 1% and bear in mind the news
  • 00:05:42
    broke just yesterday if we look at over
  • 00:05:44
    the last week it is down around 14% now
  • 00:05:48
    over the last year nothing better down
  • 00:05:50
    50% over the last 10 years down 83% and
  • 00:05:53
    it is trading even at the lower end of
  • 00:05:55
    the 52- we range yet all three analysts
  • 00:05:58
    Wall Street seeking out for and Quant do
  • 00:06:00
    give this a hold now we can also mention
  • 00:06:02
    it does currently offer a yield of
  • 00:06:04
    around 7.99% and if we were to take a
  • 00:06:06
    look at the earnings itself well over
  • 00:06:08
    the last four quarters they've actually
  • 00:06:10
    beaten three or four 75% track record
  • 00:06:13
    but we need to make you aware over the
  • 00:06:15
    next four quarters they're anticipating
  • 00:06:17
    double digit decrease to the EPS for
  • 00:06:19
    every single quarter with essentially
  • 00:06:21
    the earnings per share estimate for
  • 00:06:23
    August 20125 giving it a forward p in
  • 00:06:25
    the 7 to 7.2 region if you were to take
  • 00:06:29
    a look at how that compares against the
  • 00:06:30
    sector median well that is a lot higher
  • 00:06:32
    bearing in mind a lot of risk with this
  • 00:06:34
    company it does currently trade at a 56%
  • 00:06:37
    discount and is around 9% lower than
  • 00:06:40
    what it typically trades for on a
  • 00:06:41
    forward PE in terms of the 5year average
  • 00:06:44
    and we can show you this again on both a
  • 00:06:45
    dividend yield perspective where it is
  • 00:06:47
    at 88.8% versus the 5year however this
  • 00:06:50
    carries risks amongst itself which we
  • 00:06:52
    have covered in other episodes deeper
  • 00:06:54
    Dives on Walgreens boots Alliance and in
  • 00:06:56
    terms of the forward p as we mentioned
  • 00:06:58
    just marginally lower than the 5year
  • 00:07:00
    which you could argue just in isolation
  • 00:07:02
    is an undervaluation signal however we
  • 00:07:05
    like to do a lot more than just look at
  • 00:07:07
    one model in terms of our intrinsic
  • 00:07:09
    value again from the DCF model you can
  • 00:07:11
    in fact see here we've used 5% maybe you
  • 00:07:14
    believe that is too optimistic but based
  • 00:07:16
    on that right now we see the intrinsic
  • 00:07:18
    value at just under $11 meaning very
  • 00:07:21
    similar to 3M we don't believe there is
  • 00:07:22
    a margin of safety again for those that
  • 00:07:24
    do want to see at 10% a buy at 964 at
  • 00:07:28
    20% around $ 850 7 but with no margin of
  • 00:07:30
    safety a very similar story for Wall
  • 00:07:32
    Street in terms of what we saw with 3m
  • 00:07:34
    they see limited of 4% only at the end
  • 00:07:37
    of 2025 price Target
  • 00:07:40
    $11.44 and as always do give us your
  • 00:07:42
    thoughts in the comments below now
  • 00:07:44
    before we continue we want to let you
  • 00:07:46
    know we have released our latest free
  • 00:07:47
    weekly article we drop one every single
  • 00:07:50
    Monday morning where we cover severely
  • 00:07:52
    undervalued stocks as well as what's
  • 00:07:54
    going in the market over the last few
  • 00:07:56
    days so click below you can sign up read
  • 00:07:58
    straight away where will be able to gain
  • 00:08:00
    access to 46 undervalued stocks for the
  • 00:08:03
    month of January lots of information the
  • 00:08:05
    upside That Wall Street themselves see
  • 00:08:07
    over the next year and on top of that a
  • 00:08:09
    recently released copy of 43 stocks that
  • 00:08:11
    Wall Street themselves believe right now
  • 00:08:14
    have the most upside in the S&P so click
  • 00:08:16
    below you can sign up and read straight
  • 00:08:19
    away we then move on to Proctor and
  • 00:08:20
    Gamble that actually released their
  • 00:08:22
    earnings before the market open today
  • 00:08:24
    and they did beat estimates as they put
  • 00:08:26
    it down to Shoppers buying more
  • 00:08:28
    household Stables if we are to take a
  • 00:08:30
    look at the actual numbers that they
  • 00:08:32
    have reported the EPS as we can see a
  • 00:08:34
    marginal beat 188 versus 186 and the
  • 00:08:38
    Topline Revenue as well they did have a
  • 00:08:40
    nice beat 2.88 versus
  • 00:08:42
    2.54 and we also noticed the net income
  • 00:08:45
    comes around 188 per share which if you
  • 00:08:48
    do compare it to the same quarter last
  • 00:08:50
    year it is higher and came in at
  • 00:08:52
    $140 on top of that something we did see
  • 00:08:55
    with other companies they are struggling
  • 00:08:56
    to increase it above inflation but their
  • 00:08:58
    net sales are up 2% and if you want to
  • 00:09:01
    look at just organic Revenue still
  • 00:09:03
    slightly under than the 4% we would like
  • 00:09:05
    to see coming in at 3% in terms of their
  • 00:09:08
    volume so they are saying more of the
  • 00:09:09
    products around 1% that is good to see
  • 00:09:12
    but again something just to bear in mind
  • 00:09:14
    and we can clearly see here Proctor and
  • 00:09:15
    Gamble have seen weaker demand for their
  • 00:09:17
    products after several years of
  • 00:09:19
    constantly increasing their prices
  • 00:09:21
    ultimately what this means is that
  • 00:09:23
    consumers are moving on to cheaper
  • 00:09:25
    alternatives but over the next full year
  • 00:09:27
    they do anticipate the same earnings per
  • 00:09:30
    share as what they had guided for
  • 00:09:31
    earlier around 691 to 705 with Revenue
  • 00:09:34
    growth fairly small between 2 to 4% in
  • 00:09:37
    terms of their news they are up around 3
  • 00:09:39
    to 4% today with the market just open in
  • 00:09:42
    terms of over the last year up only 9%
  • 00:09:44
    over the last 10 years up around 92%
  • 00:09:47
    they have underformed the S&P trading in
  • 00:09:49
    the midpoint right now of the 52e range
  • 00:09:52
    with Wall Street giving this company a
  • 00:09:54
    buy rating and we can see they do
  • 00:09:56
    currently offer a yield of around 22% in
  • 00:09:59
    terms of their earnings it does look
  • 00:10:00
    good when we see green right across the
  • 00:10:02
    board meaning they anticipate growth
  • 00:10:04
    although fairly marginal over the next
  • 00:10:06
    four quarters with a 100% track record
  • 00:10:09
    and if we look to June this year and the
  • 00:10:10
    EPS Target that does give their forward
  • 00:10:13
    PE right now just marginally above 23
  • 00:10:16
    which is lower than the S smps 25 if we
  • 00:10:19
    compare it though it is at a premium
  • 00:10:20
    against the sector median in fact you
  • 00:10:22
    are paying 44% more but if we actually
  • 00:10:25
    compare it to their 5year average it
  • 00:10:27
    does come in slightly under by around 5
  • 00:10:29
    5% and based on dividend yield Theory
  • 00:10:31
    given the yield isn't far off the 5e
  • 00:10:33
    this is a reasonable signal and we also
  • 00:10:35
    note here given the forward PE of 23
  • 00:10:37
    slightly below the 5year a marginal
  • 00:10:39
    undervaluation signal but ultimately
  • 00:10:41
    when we do run it through the valuation
  • 00:10:43
    at
  • 00:10:44
    $181 it is just the average of these
  • 00:10:46
    three models we can in fact see at a 10%
  • 00:10:48
    margin of safety you would need to wait
  • 00:10:50
    for
  • 00:10:51
    $163 so right now proor and gamble
  • 00:10:53
    sitting somewhere between 5 to 10% with
  • 00:10:56
    Wall Street their buy rating they see
  • 00:10:58
    this company at 100 $90 at the end of
  • 00:11:00
    the year which does translate to 14%
  • 00:11:02
    upside we then move on to divid and King
  • 00:11:04
    Johnson Johnson that actually beat on
  • 00:11:06
    their quarterly sales as well as their
  • 00:11:08
    profit estimates and that is a very good
  • 00:11:10
    sign we have had some struggles with
  • 00:11:12
    this company especially in terms of
  • 00:11:14
    their share price and we can see they
  • 00:11:16
    expect their 2025 sales to come in
  • 00:11:18
    around 91 to 92 billion and the EPS
  • 00:11:21
    around 1075 to 1095 analy we pretty much
  • 00:11:25
    expecting something similar although on
  • 00:11:27
    the earnings per share they are are
  • 00:11:29
    anticipating a little bit higher than
  • 00:11:30
    what the market wanted to see in terms
  • 00:11:32
    of the actual sales though it is nice to
  • 00:11:34
    see above inflation up around 5.3% and
  • 00:11:37
    one of the drivers of their revenue from
  • 00:11:39
    this latest quarter is their Cancer
  • 00:11:41
    drugs up 19% worldwide driven by more
  • 00:11:44
    than 3 billion for multiple treatments
  • 00:11:46
    as we can see we can see right now it is
  • 00:11:48
    down around 4% on the earnings over the
  • 00:11:51
    last year down 12% over the last 10
  • 00:11:53
    years 39% trading pretty much near its
  • 00:11:57
    52 we low with a double buyer rating
  • 00:11:59
    from both Seeking Alpha as well as Wall
  • 00:12:01
    Street and a fairly attractive starting
  • 00:12:03
    yield for this dividend King at
  • 00:12:05
    3.37% if we were to take a look at their
  • 00:12:08
    earnings again understand they are
  • 00:12:10
    expecting some decreases over the next
  • 00:12:12
    few quarters over the last four though
  • 00:12:14
    they have continued with that beat upon
  • 00:12:16
    beat 100% track record and December 2025
  • 00:12:20
    with the EPS estimate it does give their
  • 00:12:22
    forward P right now just below 14 and if
  • 00:12:25
    we were to compare that significantly
  • 00:12:27
    low on the sector of 21 meaning you are
  • 00:12:29
    getting a 30% discount but also
  • 00:12:32
    significantly low than their 5year
  • 00:12:33
    average of around 10% and we can show
  • 00:12:36
    you on a graphical basis severe
  • 00:12:38
    undervaluation both the yield above the
  • 00:12:40
    5year the forward p as well 14.8 below
  • 00:12:43
    the 5year 16.4 so that is what we would
  • 00:12:46
    say as a double severe undervaluation
  • 00:12:48
    and when we look at our intrinsic value
  • 00:12:49
    at
  • 00:12:50
    $174 we can in fact see a fairly decent
  • 00:12:53
    margin of safety at 15% bu 148 we can
  • 00:12:56
    see if it comes around $140 you are
  • 00:12:59
    getting a 20% MOS but right now at least
  • 00:13:01
    15% with Wall Street themselves seeing
  • 00:13:04
    22% upside their price target of
  • 00:13:07
    $174 and this might be the most obvious
  • 00:13:09
    buy out of the four that we have run
  • 00:13:11
    through today and we will continue to
  • 00:13:13
    look at earnings as they come through
  • 00:13:15
    not just this week but also the next few
  • 00:13:17
    months also don't forget to sign up to
  • 00:13:19
    the free weekly news lettera we are
  • 00:13:20
    dropping one every single Monday grab
  • 00:13:22
    those spreadsheets and also come and
  • 00:13:24
    join us in the patreon where we do cover
  • 00:13:26
    our weekly buys and sells as always have
  • 00:13:28
    a great a great day and we'll see you
  • 00:13:30
    all on the next one
Tags
  • market performance
  • investor sentiment
  • earnings reports
  • 3M
  • Procter & Gamble
  • Johnson & Johnson
  • Walgreens
  • stock analysis
  • financial health
  • price targets